Pharma IT Articles

Pharma IT Hiring Trends

There was a time when information technology (IT) professionals needed only technical skills to obtain positions in the pharma and biotech industries. Today, this has all changed. Recently, the demand for skilled professionals in pharma has been hot, and that's expected to continue as 2007 unfolds.

In today's highly competitive pharma and biotech environments, hiring managers are seeking candidates with strong technical and domain skill sets, as well as extensive industry knowledge, resulting in a much more critical eye when trying to fill crucial IT positions. But with a tight job market, hiring managers will have a hard time finding candidates with a combination of tech skills and industry expertise, and will need to wade deeper than before into the talent pool.

View Full Article

Author(s): 
Jim Lanzalotto.
Journal: 
contractpharma,March 2007.

IT Governance: The Under-Leveraged Discipline

When revenue gains soften, costs start to attract greater executive attention. And so it is with Pharma. It’s widely acknowledged that the pressure to control and reduce costs is the next major challenge facing companies contributing to the Pharma industry’s global value chain. Growing generic competition, imminent patent expirations, and shorter pipelines are all contributing to eroding margins.

But as part of their efforts to improve financial performance, many pharmaceutical companies are finding it hard not to turn the cost-cutting spotlights on IT. And for good reason; not only does the Pharma industry, according to recent research, spend six times more on IT than the average U.S. industry (15% of revenues vs. 2.5%) but many companies are still waiting to chalk up measurable IT-driven business value from this huge and growing investment. It’s little wonder that pharmaceutical executives are asking why IT costs so much and yet seems to deliver so little.

Author(s): 
Marc Swenson .CONTRACT PHARMA,March 2006
Journal: 
CONTRACT PHARMA,March 2006.

Securing Your Company's Manufacturing Data

Bryan L. Singer, CISSP
The adoption of open networks in manufacturing environments, and the expanding connectivity and decentralization of computer systems and databases, are making the need to secure a company's automation and production systems more important than ever. The direct linking of manufacturing systems to information systems through the presence of Ethernet on the factory-floor creates an environment where traditional information technology (IT) and manufacturing worlds collide. This trend increases the vulnerability of these systems to the same security threats facing today's IT environments. Attacks — whether direct or indirect — from hackers, worms, viruses, and employees can affect the safety and security of people, products, processes, and productivity.

Author(s): 
Bryan L. Singer,CISSP.
Journal: 
BioPharm International, December 2005.

Focus on Quality Validation of Spectrometry Software, Part VIII

Part VIII of the series covers change control and its importance in maintaining a system's validation status.

View Full Article

Author(s): 
R.D. McDowall .
Journal: 
Spectroscopy Magazine, May 1, 2004.

Validation of an Enterprise Resource Planning (ERP) System

Jackelyn Rodriguez, Medtronic MiniMed Inc.Journal of Validation Technology , May 2003 • Volume 9, Number 3 [Enterprise Resource Planning] ERP packages enable an organization to truly function as an integrated organization.


For full text article Click Here

Author(s): 
Jackelyn Rodriguez, Medtronic MiniMed Inc.
Journal: 
Journal of Validation Technology , May 2003 • Volume 9, Number 3 .

Protecting bioinformatics’ value

As the field matures, so too must intellectual property strategies to capitalize o­n bioinformatics’ wealth. Bioinformatics—the use of computers to characterize the molecular components of living things and other biological data—is still a youngster in the life sciences family. By combining the revolutionary tools of information technology with biotechnology, bioinformatics channels the flood of information pouring from genomics and proteomics laboratories and promises to accelerate the discovery of new diagnostics and therapeutics.

For full article Click Here

Author(s): 
Michael A. Gollin.
Journal: 
Modern Drug Discovery, Oct 2004.

Remaining in a 21 CFR Part 11 Compliant State

This article provides practical advice for remaining in compliance with 21 CFR Part 11, the Electronic Records; Electronic Signatures Final Rule.1 It is directed at those who are responsible for maintaining this compliance. And just how do we do this? Descartes, in his Discours de la Methode, provided a clue when he wrote, “Each problem that I solved became a rule which served afterwards to solve other problems.” For our purpose, this translates to: remember how we got here and make sure we keep the momentum going.

For full Article Click Here

Author(s): 
Leonard A. Grunbaum.
Journal: 
Journal of GXP Compliance Volume 6 Number 3 April 2002 .

A Validation Approach for Laboratory Information Management Systems

…this paper is to discuss a potential approach to validation for LIMS. Any effective validation exercise begins with thorough planning, based upon a sound approach.

For full text article
Click Here

Author(s): 
Douglas S. Tracy,Pfizer Pharmaceutical Group Global Business Technology, Robert A. Nash, Ph.D.,New Jersey Institute of Technology.
Journal: 
Validation Technology.

Reaping the Benefits of E-Procurement

Not just a quick fix, e-procurement requires a thoughtful and thorough approach to produce the most rewards.

For full article Click Here

Author(s): 
Heather B. Hayes ,Jim Miller, PharmSource Information Services, Inc., pp.60-62.
Journal: 
BioPharm International, February 2002 .

Qualification of Network Components and Validation of Networked Systems, Part I

I n Part I of this article, the authors discuss FDA expectations, specific requirements, and validation plans of networked systems and include a glossary of related terms. Part II will address the types of specifications, the installation, testing, and implementation of required validation for networks.

For full article Click Here

Author(s): 
Ludwig Huber* ,Rory Budihandojo.
Journal: 
Pharmaceutical Technology OCTOBER 2001.
Syndicate content